Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[18F]FTPP+
- Development stage
- Unknown
- Lead developer
- Massachusetts General Hospital
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- Intravenous
01
Overview
[18F]FTPP+ (also known as [18F]FTPP or BFPET) is a fluorine-18 labeled lipophilic cationic radiopharmaceutical developed for positron emission tomography (PET) imaging. It accumulates in cells and mitochondria in a membrane potential-dependent manner, allowing for the non-invasive quantitative mapping of total cardiac membrane potential, which is the sum of cellular and mitochondrial membrane potentials. Originally developed by FluoroPharma as a myocardial perfusion imaging agent, it is being investigated by researchers at Massachusetts General Hospital and Yale University for evaluating myocardial dysfunction, such as cardioplegia-induced myocardial injury, chemotherapy-induced cardiotoxicity (e.g., doxorubicin-induced cardiotoxicity), and radiation-induced cardiac lesions.
- Other names
- (4-[18F]fluorophenyl)triphenylphosphonium18F-FTPP18F-FTPP+18F-TPP18F-TPP+18F-tetraphenylphosphonium4-[18F]fluorophenyltriphenylphosphonium[18F](4-fluorophenyl)triphenylphosphonium[18F]4-fluorophenyltriphenylphosphonium[18F]FTPP[18F]TPP[18F]TPP+[18F]tetraphenylphosphonium
Beyond the preview
Go deeper on [18F]FTPP+.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [18F]FTPP+.